Fda expands approval of dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Fda expands approv al of dupixent ® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
REGN Ratings Summary
REGN Quant Ranking